Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy
ConclusionsPatients with mRCC treated with IO had a high incidence of TE. TE was associated with risk of treatment delay, hospitalization, and mortality, while TE, IMDC poor risk, and Khorana score ≥ 2 were associated with worse survival. Further investigations into IO-associated TE are needed to identify benefit from primary thromboprophylaxis.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Thrombosis